http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CH-656618-A5
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c413c0b969a40825dbe02c04b700e66d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-14 |
| filingDate | 1982-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1620a2d9168d691a76d50ea0d998be2a |
| publicationDate | 1986-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CH-656618-A5 |
| titleOfInvention | Trimetaphan-nitroprusside, and pharmaceutical preparations containing this compound |
| abstract | Novel pharmaceutical products, which contain trimetaphan in addition to nitroprusside and which are superior in activity, are described. Those products are the novel complex salt bis(trimetaphan)-nitroprusside and its hydrate, as well as synergistic mixtures which contain nitroprusside in addition to trimetaphan. The preparation of these complex salts, mixtures and solutions is also described. In a special embodiment, the novel bis(trimetaphan)-nitroprusside is obtained by reacting (+)-trimetaphan camsylate with sodium nitroprusside in a ratio by weight of 4:1 in water. As compared with the known individual active compounds trimetaphan camyslate and sodium nitroprusside, bis(trimetaphan)-nitroprusside exhibits a synergistically increased activity and, owing to the possibility of lower dosage rates which this entails, substantially lower toxicity and fewer side effects. Bis(trimetaphan)-nitroprusside is suitable for therapeutic use, in particular for rapidly lowering blood pressure in a selective manner, for relieving peripheral and life-threatening circulatory disturbances as a consequence of peripheral vasoconstriction and vasospasms, and for use in myocardial infarction. It is to be emphasised that the outstanding ability to control the effect of nitroprusside is fully preserved in the case of bis(trimetaphan)-nitroprusside, in spite of the substantially longer half-life of the trimetaphan component. On the other hand, the undesirable effects which can be observed with nitroprusside, such as resistance or rebound following rapid discontinuation of the preparation, are not observed in the case of bis(trimetaphan)- nitroprusside. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014122074-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2764868-A1 |
| priorityDate | 1982-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.